Article info
PDFClinical science
Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation
- Correspondence to Professor Xiaoyan Ding, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China; dingxy75{at}gmail.com
Citation
Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation
Publication history
- Received January 4, 2020
- Revised February 20, 2020
- Accepted February 27, 2020
- First published March 11, 2020.
Online issue publication
December 11, 2020
Article Versions
- Previous version (11 March 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.